Latest Information Update: 19 Feb 2007
At a glance
- Originator AstraZeneca
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Gastrointestinal disorders
Most Recent Events
- 07 Jul 2006 This compound is still in active development for functional gastrointestinal disease (AstraZeneca development pipeline 2006)
- 02 Mar 2005 Preclinical trials in Gastrointestinal disorders in Europe (unspecified route)